Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-4127

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-4127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 50mg (Losartan 50 mg 30s)

The text provides information about Losartan Potassium tablets, a generic for Cozaar, containing 50mg of Losartan potassium. It includes details such as expiration date, storage instructions, manufacturer (Macleods Pharmaceuticals Ltd.), and precautions against transferring the medication to anyone other than the prescribed patient. The tablets are described as oval, white, scored, and imprinted with "CL 14." The text also mentions a "Billing Chart Log" section.*

FDA Label Image

Fig.3 (Losartan Figure No 3)

This text appears to provide a tabular presentation of overall results from a study, including demographic categories such as age, gender, race, and various health conditions like diabetes, history of CVD, and measures related to ISH (possibly indicating hypertension) among other variables. The table seems to compare rates and hazard ratios of events in different treatment groups (Losartan-K, Atenolol) for stroke outcomes in the study population. It also mentions different variables such as the number of events and patients in each category. The study also seems to indicate the comparison of flavors of Losartan-K and Atenolol.*

FDA Label Image

Fig.1 (Losartan Figure1)

This text provides data on the percentage of patients with the primary endpoint in a study comparing Losartan Potassium and Atenolol. It includes information on the adjusted risk reduction (13%) and the study month timeline (from 12 to 68 months).*

FDA Label Image

Fig.2 (Losartan Figure2)

This text appears to be providing information about the adjusted risk reduction of 26% with a statistical significance of p=0.001 for Atenolol and Losartan Potassium in relation to the percentage of patients with fatal/nonfatal stroke over different study months. The data is presented in a chart showing the study months on the x-axis and the percentage of patients on the y-axis.*

FDA Label Image

Fig.4 (Losartan Figure4)

This data includes the percentage of patients with events, indicating a risk reduction of 16.1% when comparing Losartan Potassium to Placebo. The p-value is given as 0.0022, suggesting statistical significance. The observation period is 24 months, with the number of events recorded over this time period for each group.*

FDA Label Image

Str (Losartan Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.